Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Olaparib in Subjects With Malignant Mesothelioma

Next Previous
Trial Profile

Phase II Study of Olaparib in Subjects With Malignant Mesothelioma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 29 Jun 2018 to 16 Jul 2018.
    • 03 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 23 Jun 2018 Planned initiation date changed from 4 Jun 2018 to 26 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top